<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121497</url>
  </required_header>
  <id_info>
    <org_study_id>5759</org_study_id>
    <nct_id>NCT01121497</nct_id>
  </id_info>
  <brief_title>The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of physostigmine in
      combination with sedation for colonoscopy can minimize the cognitive decline at the time of
      hospital discharge
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physostigmine, a tertiary cholinesterase inhibitor, which prevents the breakdown of ACh by
      inhibiting the enzyme acetylcholinesterase (AChE), crosses the blood-brain barrier (BBB), and
      elevates brain ACh levels. Physostigmine has been shown to improve attention, and performance
      in working memory. It has also been shown to produce analgesia following systemic or central
      administration.

      Patients undergoing colonoscopy under sedation of propofol and fentanyl show cognitive
      decline in the immediate period following the procedure. In this study, half the patients
      will receive physostigmine in combination with the sedation, and their cognitive functioning
      at the time of hospital discharge will be assessed by standard neuropsychological tests, and
      compared to that of patients without physostigmine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive functioning assessed by standard neuropsychological tests</measure>
    <time_frame>At time of hospital discharge following colonoscopy procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Physostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopy sedation with or without physostigmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physostigmine</intervention_name>
    <description>Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure</description>
    <arm_group_label>Physostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over18 years old

          -  ASA I-III

          -  Fluency in Hebrew, Russian, or Arabic

          -  Absence of serious hearing or vision impairment

        Exclusion Criteria:

          -  History of head trauma, neurological diseases, alcoholism, drug abuse, consumption of
             psychotropic drugs or antidepressants

          -  Heart failure (NYHA &gt; 3)

          -  Liver failure

          -  Respiratory problems (asthma, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bezion Beilin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasharon Hospital, Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benzion Beilin, MD</last_name>
    <phone>972-3-937-2469</phone>
    <email>beilinb@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hasharon Hospital, Rabin Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benzion Beilin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>May 11, 2010</last_update_submitted>
  <last_update_submitted_qc>May 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Benzion Beilin</name_title>
    <organization>Hasharon Hospital, Rabin Medical Center</organization>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Cognitive decline</keyword>
  <keyword>Physostigmine</keyword>
  <keyword>Colonoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

